Outcomes of Kidney Transplantation in Scleroderma Patients: A U.S. National Database Study

Clicks: 7
ID: 339651
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #232 of 233 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 233 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Background Scleroderma is a systemic autoimmune disease that can progress to end-stage renal disease. Historically, kidney transplantation in scleroderma patients was associated with poor outcomes, but contemporary results in the United States remain understudied. Methods Adult kidney transplant recipients with scleroderma (1990-2020) were identified from the SRTR database. Control groups included patients with diabetes mellitus, IgA nephropathy, and all non-scleroderma recipients. Kaplan-Meier methods were used to estimate patient survival and graft survival. Results Among 347,598 kidney transplant recipients, 399 had scleroderma. Compared with non-scleroderma recipients, those with scleroderma were more likely to receive a living donor transplant (45.1% vs. 34.3%, p<0.001), be female (77.9% vs. 39.3%, p<0.001), be white (86.5% vs. 66.8%, p<0.001), and have a lower body mass index (22.9 vs. 27.1 kg/m², p<0.001). After adjustment for various factors, scleroderma was associated with higher mortality compared with non-scleroderma recipients (HR 1.39, 95% CI 1.19–1.65) and recipients with IgA nephropathy (HR 2.98, 95% CI 2.48–3.58), but comparable to recipients with diabetes mellitus (HR 0.88, 95% CI 0.75–1.04). Death-censored graft survival was comparable between recipients with scleroderma and those with diabetes mellitus (HR 0.91, 95% CI 0.69–1.19) or non-scleroderma recipients (HR 1.27, 95% CI 0.97–1.67), but was inferior compared with recipients with IgA nephropathy (HR 2.11, 95% CI 1.59–2.80). Conclusion Outcomes of kidney transplantation in scleroderma patients are similar to patients with diabetes but inferior to patients with IgA nephropathy and kidney transplant is a viable option for scleroderma patients with end stage kidney disease.
Reference Key
openalex_W7225910795 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag400
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.